Ranking · Trials
Active Phase III trials
Active interventional studies with PHASE3 among their phases, mapped to this cancer or its descendants.
Computedci-phase3-trials-v1unit: counthigher = betterAll metrics
| Rank | Δ | Cancer | Active Phase III trials (count) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Neoplasm | 2,495 | 100 | Medium confidence | clinicaltrials | inputs
ranking row 2583886 |
| 2 | = | Carcinoma | 1,079 | 99.9 | Medium confidence | clinicaltrials | inputs
ranking row 2583887 |
| 3 | = | Secondary Malignant Neoplasm | 544 | 99.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583888 |
| 4 | = | Malignant Neoplasm of Unknown Primary | 540 | 99.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583889 |
| 5 | = | Carcinoma of Unknown Primary | 538 | 99.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583890 |
| 6 | = | Malignant Digestive System Neoplasm | 515 | 99.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583891 |
| 7 | = | Malignant Genitourinary System Neoplasm | 425 | 99.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583892 |
| 8 | = | Malignant Thoracic Neoplasm | 387 | 99.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583893 |
| 9 | = | Malignant Lung Neoplasm | 382 | 99 | Medium confidence | clinicaltrials | inputs
ranking row 2583895 |
| 9 | = | Malignant Respiratory System Neoplasm | 382 | 99 | Medium confidence | clinicaltrials | inputs
ranking row 2583894 |
| 11 | = | Lung Carcinoma | 359 | 98.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583896 |
| 12 | = | Adenocarcinoma | 341 | 98.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583897 |
| 13 | = | Malignant Reproductive System Neoplasm | 323 | 98.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583898 |
| 14 | = | Malignant Breast Neoplasm | 320 | 98.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583899 |
| 15 | = | Non-Small Cell Carcinoma | 299 | 98.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583900 |
| 16 | = | Lung Non-Small Cell Carcinoma | 298 | 98.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583901 |
| 17 | = | Lymphoid Neoplasm | 282 | 98 | Medium confidence | clinicaltrials | inputs
ranking row 2583902 |
| 18 | = | Lymphoma | 281 | 97.9 | Medium confidence | clinicaltrials | inputs
ranking row 2583903 |
| 19 | = | B-Cell Malignant Neoplasm | 261 | 97.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583904 |
| 20 | = | Non-Hodgkin Lymphoma | 252 | 97.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583905 |
| 21 | = | Digestive System Carcinoma | 234 | 97.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583906 |
| 22 | = | B-Cell Non-Hodgkin Lymphoma | 226 | 97.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583907 |
| 23 | = | Malignant Intestinal Neoplasm | 194 | 97.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583908 |
| 24 | = | Leukemia | 190 | 97.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583909 |
| 24 | = | Malignant Head and Neck Neoplasm | 190 | 97.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583910 |
| 24 | = | Malignant Large Intestinal Neoplasm | 190 | 97.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583911 |
| 27 | = | Malignant Colorectal Neoplasm | 183 | 96.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583912 |
| 28 | = | Genitourinary System Carcinoma | 180 | 96.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583913 |
| 29 | = | Malignant Female Reproductive System Neoplasm | 173 | 96.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583914 |
| 30 | = | Head and Neck Carcinoma | 162 | 96.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583915 |
| 31 | = | Digestive System Adenocarcinoma | 153 | 96.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583916 |
| 31 | = | Malignant Male Reproductive System Neoplasm | 153 | 96.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583917 |
| 33 | = | Malignant Prostate Neoplasm | 148 | 96 | Medium confidence | clinicaltrials | inputs
ranking row 2583918 |
| 34 | = | Hepatopancreatobiliary Carcinoma | 137 | 95.9 | Medium confidence | clinicaltrials | inputs
ranking row 2583919 |
| 35 | = | Acute Leukemia | 131 | 95.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583920 |
| 36 | = | Malignant Neck Neoplasm | 129 | 95.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583921 |
| 37 | = | Malignant Hepatobiliary Neoplasm | 124 | 95.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583922 |
| 38 | = | Malignant Bone Marrow Neoplasm | 120 | 95.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583923 |
| 39 | = | Breast Carcinoma | 117 | 95.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583924 |
| 40 | = | Multiple Myeloma | 115 | 95.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583925 |
| 41 | = | Malignant Pharyngeal Neoplasm | 114 | 95.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583926 |
| 42 | = | Squamous Cell Carcinoma | 113 | 94.9 | Medium confidence | clinicaltrials | inputs
ranking row 2583927 |
| 43 | = | Neck Carcinoma | 112 | 94.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583928 |
| 44 | = | Myeloproliferative Neoplasm | 110 | 94.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583929 |
| 45 | = | Malignant Urinary System Neoplasm | 106 | 94.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583930 |
| 45 | = | Pharyngeal Carcinoma | 106 | 94.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583931 |
| 45 | = | Throat Carcinoma | 106 | 94.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583932 |
| 48 | = | Breast Adenocarcinoma | 99 | 94.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583933 |
| 49 | = | Malignant Nasopharyngeal Neoplasm | 97 | 94.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583935 |
| 49 | = | Mature B-Cell Non-Hodgkin Lymphoma | 97 | 94.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583934 |
| 51 | = | Nasopharyngeal Carcinoma | 95 | 93.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583936 |
| 52 | = | Malignant Liver Neoplasm | 94 | 93.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583937 |
| 53 | = | Malignant Uterine Neoplasm | 92 | 93.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583939 |
| 53 | = | Myeloid Leukemia | 92 | 93.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583938 |
| 55 | = | Malignant Ovarian Neoplasm | 89 | 93.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583940 |
| 55 | = | Primary Malignant Liver Neoplasm | 89 | 93.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583941 |
| 57 | = | Liver Carcinoma | 88 | 93.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583942 |
| 58 | = | Acute Myeloid Leukemia | 86 | 93 | Medium confidence | clinicaltrials | inputs
ranking row 2583944 |
| 58 | = | Lymphoid Leukemia | 86 | 93 | Medium confidence | clinicaltrials | inputs
ranking row 2583943 |
| 60 | = | Invasive Carcinoma | 84 | 92.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583946 |
| 60 | = | Invasive Malignant Neoplasm | 84 | 92.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583945 |
| 60 | = | Urinary System Carcinoma | 84 | 92.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583947 |
| 63 | = | Hepatocellular Carcinoma | 82 | 92.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583948 |
| 64 | = | Breast Carcinoma by Gene Expression Profile | 79 | 92.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583949 |
| 65 | = | Malignant Gastric Neoplasm | 78 | 92.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583950 |
| 66 | = | Endocrine Carcinoma | 74 | 92 | Medium confidence | clinicaltrials | inputs
ranking row 2583952 |
| 66 | = | Malignant Endocrine Neoplasm | 74 | 92 | Medium confidence | clinicaltrials | inputs
ranking row 2583951 |
| 68 | = | Neuroendocrine Carcinoma | 70 | 91.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583953 |
| 69 | = | Malignant Esophageal Neoplasm | 69 | 91.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583954 |
| 69 | = | Malignant Pancreatic Neoplasm | 69 | 91.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583955 |
| 71 | = | Malignant Urinary Tract Neoplasm | 65 | 91.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583956 |
| 72 | = | Esophageal and Gastroesophageal Junction Carcinoma | 64 | 91.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583957 |
| 72 | = | Malignant Anorectal Neoplasm | 64 | 91.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583958 |
| 74 | = | Lung Neuroendocrine Carcinoma | 62 | 91 | Medium confidence | clinicaltrials | inputs
ranking row 2583960 |
| 74 | = | Lung Small Cell Carcinoma | 62 | 91 | Medium confidence | clinicaltrials | inputs
ranking row 2583962 |
| 74 | = | Melanoma | 62 | 91 | Medium confidence | clinicaltrials | inputs
ranking row 2583959 |
| 74 | = | Small Cell Neuroendocrine Carcinoma | 62 | 91 | Medium confidence | clinicaltrials | inputs
ranking row 2583961 |
| 78 | = | Head and Neck Squamous Cell Carcinoma | 59 | 90.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583963 |
| 78 | = | Malignant Cervical Neoplasm | 59 | 90.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583964 |
| 80 | = | Malignant Rectal Neoplasm | 57 | 90.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583965 |
| 81 | = | Malignant Nervous System Neoplasm | 56 | 90.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583966 |
| 81 | = | Pancreatobiliary Carcinoma | 56 | 90.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583967 |
| 83 | = | Female Reproductive System Carcinoma | 53 | 89.9 | Medium confidence | clinicaltrials | inputs
ranking row 2583969 |
| 83 | = | Precursor Lymphoid Neoplasm | 53 | 89.9 | Medium confidence | clinicaltrials | inputs
ranking row 2583968 |
| 85 | = | Acute Lymphoblastic Leukemia | 50 | 89.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583970 |
| 85 | = | Triple-Negative Breast Carcinoma | 50 | 89.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583971 |
| 87 | = | Malignant Bladder Neoplasm | 48 | 89.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583972 |
| 88 | = | Malignant Central Nervous System Neoplasm | 47 | 89.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583973 |
| 89 | = | Malignant Kidney Neoplasm | 46 | 89.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583974 |
| 90 | = | Esophageal Carcinoma | 45 | 89 | Medium confidence | clinicaltrials | inputs
ranking row 2583975 |
| 90 | = | Male Reproductive System Carcinoma | 45 | 89 | Medium confidence | clinicaltrials | inputs
ranking row 2583976 |
| 90 | = | Urinary Tract Carcinoma | 45 | 89 | Medium confidence | clinicaltrials | inputs
ranking row 2583977 |
| 93 | = | Chronic Leukemia | 44 | 88.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583978 |
| 93 | = | Kidney Carcinoma | 44 | 88.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583979 |
| 93 | = | Prostate Carcinoma | 44 | 88.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583980 |
| 96 | = | Malignant Uterine Corpus Neoplasm | 41 | 88.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583981 |
| 97 | = | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 39 | 88.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583982 |
| 97 | = | Renal Cell Carcinoma | 39 | 88.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583984 |
| 97 | = | Urinary System Adenocarcinoma | 39 | 88.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583983 |
| 100 | = | Pancreatic Carcinoma | 38 | 87.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583985 |
| 101 | = | Anaplastic Malignant Neoplasm | 37 | 87.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583986 |
| 101 | = | Diffuse Large B-Cell Lymphoma | 37 | 87.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583991 |
| 101 | = | Malignant Biliary Tract Neoplasm | 37 | 87.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583989 |
| 101 | = | Malignant Ovarian Epithelial Tumor | 37 | 87.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583987 |
| 101 | = | Ovarian Carcinoma | 37 | 87.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583990 |
| 101 | = | Transitional Cell Carcinoma | 37 | 87.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583988 |
| 107 | = | Adult-Type Diffuse Glioma | 36 | 86.9 | Medium confidence | clinicaltrials | inputs
ranking row 2583994 |
| 107 | = | Chronic Lymphocytic Leukemia | 36 | 86.9 | Medium confidence | clinicaltrials | inputs
ranking row 2583993 |
| 107 | = | Sarcoma | 36 | 86.9 | Medium confidence | clinicaltrials | inputs
ranking row 2583992 |
| 110 | = | Esophageal Squamous Cell Carcinoma | 35 | 86.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583995 |
| 110 | = | Malignant Endometrial Neoplasm | 35 | 86.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583996 |
| 112 | = | Intestinal Carcinoma | 33 | 86.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583997 |
| 113 | = | Lung Non-Squamous Non-Small Cell Carcinoma | 32 | 86.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583999 |
| 113 | = | Malignant Colon Neoplasm | 32 | 86.2 | Medium confidence | clinicaltrials | inputs
ranking row 2584000 |
| 113 | = | Malignant Glioma | 32 | 86.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583998 |
| 116 | = | Exocrine Pancreas Carcinoma | 31 | 85.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584002 |
| 116 | = | High Grade Astrocytic Tumor | 31 | 85.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584003 |
| 116 | = | Malignant Exocrine Pancreas Neoplasm | 31 | 85.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584001 |
| 116 | = | Pancreatic Adenocarcinoma | 31 | 85.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584004 |
| 116 | = | WHO Grade 4 Glioma | 31 | 85.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584005 |
| 121 | = | Malignant Fallopian Tube Neoplasm | 30 | 85.2 | Medium confidence | clinicaltrials | inputs
ranking row 2584006 |
| 122 | = | Glioblastoma | 29 | 85 | Medium confidence | clinicaltrials | inputs
ranking row 2584007 |
| 122 | = | HER2-Positive Breast Carcinoma | 29 | 85 | Medium confidence | clinicaltrials | inputs
ranking row 2584009 |
| 122 | = | Urothelial Carcinoma | 29 | 85 | Medium confidence | clinicaltrials | inputs
ranking row 2584008 |
| 125 | = | Gastroesophageal Junction Adenocarcinoma | 27 | 84.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584010 |
| 125 | = | Gastroesophageal Junction Carcinoma | 27 | 84.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584011 |
| 127 | = | Colorectal Carcinoma | 26 | 84.4 | Medium confidence | clinicaltrials | inputs
ranking row 2584013 |
| 127 | = | Follicular Lymphoma | 26 | 84.4 | Medium confidence | clinicaltrials | inputs
ranking row 2584014 |
| 127 | = | Malignant Skin Neoplasm | 26 | 84.4 | Medium confidence | clinicaltrials | inputs
ranking row 2584012 |
| 130 | = | Bladder Carcinoma | 25 | 84.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584015 |
| 131 | = | Cervical Carcinoma | 23 | 83.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584018 |
| 131 | = | Female Reproductive System Adenocarcinoma | 23 | 83.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584017 |
| 131 | = | Malignant Soft Tissue Neoplasm | 23 | 83.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584016 |
| 134 | = | Gastric Carcinoma | 22 | 83.6 | Medium confidence | clinicaltrials | inputs
ranking row 2584021 |
| 134 | = | Myelodysplastic Syndrome | 22 | 83.6 | Medium confidence | clinicaltrials | inputs
ranking row 2584019 |
| 134 | = | Non-Hodgkin Lymphoma by Clinical Course | 22 | 83.6 | Medium confidence | clinicaltrials | inputs
ranking row 2584022 |
| 134 | = | Soft Tissue Sarcoma | 22 | 83.6 | Medium confidence | clinicaltrials | inputs
ranking row 2584020 |
| 138 | = | Castration-Resistant Prostate Carcinoma | 21 | 83.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584025 |
| 138 | = | Malignant Mixed Neoplasm | 21 | 83.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584023 |
| 138 | = | Malignant Peritoneal and Retroperitoneal Neoplasm | 21 | 83.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584024 |
| 141 | = | Biliary Tract Carcinoma | 20 | 82.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584029 |
| 141 | = | B Lymphoblastic Leukemia/Lymphoma | 20 | 82.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584027 |
| 141 | = | Childhood Malignant Neoplasm | 20 | 82.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584026 |
| 141 | = | Malignant Peritoneal Neoplasm | 20 | 82.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584028 |
| 141 | = | Pancreatic Ductal Adenocarcinoma | 20 | 82.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584030 |
| 146 | = | B Acute Lymphoblastic Leukemia | 19 | 82.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584032 |
| 146 | = | Cervical Adenocarcinoma | 19 | 82.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584033 |
| 146 | = | Cervical Non-Squamous Cell Carcinoma | 19 | 82.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584035 |
| 146 | = | Malignant Solid Neoplasm | 19 | 82.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584031 |
| 146 | = | T-Cell Non-Hodgkin Lymphoma | 19 | 82.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584034 |
| 151 | = | Cholangiocarcinoma | 18 | 81.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584038 |
| 151 | = | Intraductal Papillary Neoplasm of the Bile Duct | 18 | 81.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584040 |
| 151 | = | Malignant Bile Duct Neoplasm | 18 | 81.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584036 |
| 151 | = | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | 18 | 81.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584039 |
| 151 | = | Small Lymphocytic Lymphoma | 18 | 81.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584037 |
| 156 | = | Clear Cell Adenocarcinoma | 17 | 80.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584043 |
| 156 | = | Gastric Adenocarcinoma | 17 | 80.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584046 |
| 156 | = | Head and Neck Mucosal Squamous Cell Carcinoma | 17 | 80.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584044 |
| 156 | = | Malignant Head and Neck Mucosal Neoplasm | 17 | 80.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584041 |
| 156 | = | Malignant Lip and Oral Cavity Neoplasm | 17 | 80.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584042 |
| 156 | = | Myeloproliferative Neoplasm, BCR-ABL1 Negative | 17 | 80.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584045 |
| 162 | = | Invasive Bladder Carcinoma | 16 | 80.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584048 |
| 162 | = | Invasive Prostate Carcinoma | 16 | 80.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584049 |
| 162 | = | Lymphoma by Site | 16 | 80.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584047 |
| 162 | = | Prostate Adenocarcinoma | 16 | 80.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584050 |
| 166 | = | Invasive Breast Carcinoma | 15 | 79.6 | Medium confidence | clinicaltrials | inputs
ranking row 2584051 |
| 166 | = | Malignant Oropharyngeal Neoplasm | 15 | 79.6 | Medium confidence | clinicaltrials | inputs
ranking row 2584053 |
| 166 | = | Malignant Thyroid Gland Neoplasm | 15 | 79.6 | Medium confidence | clinicaltrials | inputs
ranking row 2584052 |
| 169 | = | Colorectal Adenocarcinoma | 14 | 79.2 | Medium confidence | clinicaltrials | inputs
ranking row 2584059 |
| 169 | = | Lip and Oral Cavity Carcinoma | 14 | 79.2 | Medium confidence | clinicaltrials | inputs
ranking row 2584057 |
| 169 | = | Mixed Carcinoma | 14 | 79.2 | Medium confidence | clinicaltrials | inputs
ranking row 2584054 |
| 169 | = | Ovarian Adenocarcinoma | 14 | 79.2 | Medium confidence | clinicaltrials | inputs
ranking row 2584060 |
| 169 | = | Primary Peritoneal Carcinoma | 14 | 79.2 | Medium confidence | clinicaltrials | inputs
ranking row 2584055 |
| 169 | = | Serous Adenocarcinoma | 14 | 79.2 | Medium confidence | clinicaltrials | inputs
ranking row 2584058 |
| 169 | = | Skin Carcinoma | 14 | 79.2 | Medium confidence | clinicaltrials | inputs
ranking row 2584056 |
| 176 | = | Endometrioid Adenocarcinoma | 13 | 78.4 | Medium confidence | clinicaltrials | inputs
ranking row 2584062 |
| 176 | = | Female Reproductive System Endometrioid Adenocarcinoma | 13 | 78.4 | Medium confidence | clinicaltrials | inputs
ranking row 2584063 |
| 176 | = | Lip and Oral Cavity Squamous Cell Carcinoma | 13 | 78.4 | Medium confidence | clinicaltrials | inputs
ranking row 2584065 |
| 176 | = | Malignant Eye Neoplasm | 13 | 78.4 | Medium confidence | clinicaltrials | inputs
ranking row 2584061 |
| 176 | = | Malignant Oral Cavity Neoplasm | 13 | 78.4 | Medium confidence | clinicaltrials | inputs
ranking row 2584064 |
| 176 | = | Oral Cavity Carcinoma | 13 | 78.4 | Medium confidence | clinicaltrials | inputs
ranking row 2584066 |
| 182 | = | Aggressive Non-Hodgkin Lymphoma | 12 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2584068 |
| 182 | = | Hodgkin Lymphoma | 12 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2584067 |
| 182 | = | Oral Cavity Squamous Cell Carcinoma | 12 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2584069 |
| 185 | = | Encapsulated Glioma | 11 | 77.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584077 |
| 185 | = | Erythroid Neoplasm | 11 | 77.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584070 |
| 185 | = | Fallopian Tube Carcinoma | 11 | 77.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584073 |
| 185 | = | Indolent Non-Hodgkin Lymphoma | 11 | 77.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584074 |
| 185 | = | Malignant Ovarian Serous Tumor | 11 | 77.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584071 |
| 185 | = | Ovarian Serous Adenocarcinoma | 11 | 77.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584075 |
| 185 | = | Polycythemia Vera | 11 | 77.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584072 |
| 185 | = | Rectal Carcinoma | 11 | 77.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584076 |
| 193 | = | Bladder Urothelial Carcinoma | 10 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584083 |
| 193 | = | Indolent B-Cell Non-Hodgkin Lymphoma | 10 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584084 |
| 193 | = | Lung Adenocarcinoma | 10 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584085 |
| 193 | = | Malignant Musculoskeletal Neoplasm | 10 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584078 |
| 193 | = | Mantle Cell Lymphoma | 10 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584086 |
| 193 | = | Non-Cutaneous Melanoma | 10 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584080 |
| 193 | = | Non-Muscle Invasive Bladder Carcinoma | 10 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584087 |
| 193 | = | Non-Small Cell Adenocarcinoma | 10 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584081 |
| 193 | = | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 10 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584088 |
| 193 | = | Primitive Neuroectodermal Tumor | 10 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584079 |
| 193 | = | Renal Pelvis and Ureter Carcinoma | 10 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584082 |
| 204 | = | Adenosquamous Carcinoma | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584097 |
| 204 | = | Carcinoma In Situ | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584089 |
| 204 | = | Clear Cell Renal Cell Carcinoma | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584102 |
| 204 | = | Glioblastoma, IDH-Wildtype | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584098 |
| 204 | = | Malignant Hypopharyngeal Neoplasm | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584103 |
| 204 | = | Malignant Laryngeal Neoplasm | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584099 |
| 204 | = | Malignant Muscle Neoplasm | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584090 |
| 204 | = | Malignant Ovarian Endometrioid Tumor | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584100 |
| 204 | = | Malignant Uveal Neoplasm | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584091 |
| 204 | = | Myosarcoma | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584092 |
| 204 | = | Neuroblastic Tumor | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584093 |
| 204 | = | Neuroblastoma | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584101 |
| 204 | = | Ocular Melanoma | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584094 |
| 204 | = | Oropharyngeal Carcinoma | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584106 |
| 204 | = | Ovarian Endometrioid Adenocarcinoma | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584104 |
| 204 | = | Pharyngeal Squamous Cell Carcinoma | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584105 |
| 204 | = | Undifferentiated Carcinoma | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584095 |
| 204 | = | Uveal Melanoma | 9 | 74.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584096 |
| 222 | = | Adult Acute Myeloid Leukemia | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584112 |
| 222 | = | Breast Ductal Carcinoma | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584113 |
| 222 | = | Endometrial Carcinoma | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584114 |
| 222 | = | Esophageal Adenocarcinoma | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584115 |
| 222 | = | Fallopian Tube Adenocarcinoma | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584116 |
| 222 | = | Female Reproductive System Clear Cell Adenocarcinoma | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584117 |
| 222 | = | Hypopharyngeal Carcinoma | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584120 |
| 222 | = | Infection-Related Malignant Neoplasm | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584107 |
| 222 | = | Oropharyngeal Squamous Cell Carcinoma | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584121 |
| 222 | = | Primary Myelofibrosis | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584118 |
| 222 | = | Renal Pelvis and Ureter Urothelial Carcinoma | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584119 |
| 222 | = | Skin Squamous Cell Carcinoma | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584110 |
| 222 | = | T Acute Lymphoblastic Leukemia | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584111 |
| 222 | = | T Lymphoblastic Leukemia/Lymphoma | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584108 |
| 222 | = | Virus-Related Malignant Neoplasm | 8 | 72.7 | Medium confidence | clinicaltrials | inputs
ranking row 2584109 |
| 237 | = | Acute Myeloid Leukemia with Genetic Abnormalities | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584128 |
| 237 | = | Adenocarcinoma In Situ | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584123 |
| 237 | = | Aggressive T-Cell Non-Hodgkin Lymphoma | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584129 |
| 237 | = | Basal Cell Carcinoma | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584122 |
| 237 | = | Early Stage Breast Carcinoma | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584124 |
| 237 | = | Female Reproductive System Undifferentiated Carcinoma | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584125 |
| 237 | = | Laryngeal Carcinoma | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584130 |
| 237 | = | Malignant Anal Neoplasm | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584135 |
| 237 | = | Malignant Brain Neoplasm | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584131 |
| 237 | = | Malignant Intracranial Neoplasm | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584126 |
| 237 | = | Non-Clear Cell Renal Cell Carcinoma | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584136 |
| 237 | = | Platinum-Resistant Malignant Female Reproductive System Neoplasm | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584132 |
| 237 | = | Platinum-Resistant Ovarian Carcinoma | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584133 |
| 237 | = | Primary Peritoneal Adenocarcinoma | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584127 |
| 237 | = | Primary Peritoneal Serous Adenocarcinoma | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584134 |
| 237 | = | Rectal Adenocarcinoma | 7 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2584137 |
| 253 | = | Acute Leukemia of Ambiguous Lineage | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584143 |
| 253 | = | Acute Promyelocytic Leukemia | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584160 |
| 253 | = | Breast Carcinoma In Situ | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584152 |
| 253 | = | Central Nervous System Lymphoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584138 |
| 253 | = | Childhood Acute Leukemia | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584144 |
| 253 | = | Childhood Acute Lymphoblastic Leukemia | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584145 |
| 253 | = | Childhood Leukemia | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584139 |
| 253 | = | Colon Carcinoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584157 |
| 253 | = | Cutaneous Melanoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584140 |
| 253 | = | Hypopharyngeal Squamous Cell Carcinoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584158 |
| 253 | = | Intrahepatic Cholangiocarcinoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584146 |
| 253 | = | Laryngeal Squamous Cell Carcinoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584153 |
| 253 | = | Lymphoblastic Lymphoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584141 |
| 253 | = | Malignant Ovarian Clear Cell Tumor | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584147 |
| 253 | = | Marginal Zone Lymphoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584159 |
| 253 | = | Mixed Phenotype Acute Leukemia | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584154 |
| 253 | = | Mucinous Adenocarcinoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584148 |
| 253 | = | Muscle Invasive Bladder Carcinoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584155 |
| 253 | = | Papillary Carcinoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584142 |
| 253 | = | Primary Central Nervous System Lymphoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584149 |
| 253 | = | Rhabdomyosarcoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584150 |
| 253 | = | Thyroid Gland Carcinoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584156 |
| 253 | = | Uterine Corpus Sarcoma | 6 | 68.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584151 |
| 276 | = | Aggressive B-Cell Non-Hodgkin Lymphoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584166 |
| 276 | = | Breast Ductal Carcinoma In Situ | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584167 |
| 276 | = | Carcinosarcoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584161 |
| 276 | = | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584168 |
| 276 | = | Classic Hodgkin Lymphoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584169 |
| 276 | = | Colon Adenocarcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584187 |
| 276 | = | Digestive System Adenosquamous Carcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584170 |
| 276 | = | Extrapulmonary Neuroendocrine Carcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584171 |
| 276 | = | Fallopian Tube Clear Cell Adenocarcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584188 |
| 276 | = | Fallopian Tube Endometrioid Adenocarcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584172 |
| 276 | = | Fallopian Tube Serous Adenocarcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584179 |
| 276 | = | Fallopian Tube Transitional Cell Carcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584180 |
| 276 | = | Female Reproductive System Transitional Cell Carcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584173 |
| 276 | = | Ganglioneuroblastoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584174 |
| 276 | = | HER2-Negative Breast Carcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584181 |
| 276 | = | Human Papillomavirus-Related Carcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584175 |
| 276 | = | Human Papillomavirus-Related Malignant Neoplasm | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584176 |
| 276 | = | Intraductal Carcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584162 |
| 276 | = | Malignant Ureter Neoplasm | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584182 |
| 276 | = | Myelodysplastic/Myeloproliferative Neoplasm | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584163 |
| 276 | = | Oligometastatic Malignant Neoplasm | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584164 |
| 276 | = | Ovarian Clear Cell Adenocarcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584183 |
| 276 | = | Ovarian Seromucinous Carcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584177 |
| 276 | = | Ovarian Transitional Cell Carcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584184 |
| 276 | = | Ovarian Undifferentiated Carcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584185 |
| 276 | = | Pancreatic Adenosquamous Carcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584186 |
| 276 | = | Papillary Adenocarcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584178 |
| 276 | = | Virus-Related Carcinoma | 5 | 66 | Medium confidence | clinicaltrials | inputs
ranking row 2584165 |
| 304 | = | Alveolar Rhabdomyosarcoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584205 |
| 304 | = | Anaplastic Large Cell Lymphoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584190 |
| 304 | = | Carcinomatosis | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584192 |
| 304 | = | Chronic Myelomonocytic Leukemia | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584193 |
| 304 | = | Differentiated Thyroid Gland Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584206 |
| 304 | = | Embryonal Rhabdomyosarcoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584207 |
| 304 | = | Endometrial Adenocarcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584208 |
| 304 | = | Endometrial Endometrioid Adenocarcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584209 |
| 304 | = | Extranodal Lymphoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584194 |
| 304 | = | Extranodal Non-Hodgkin Lymphoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584195 |
| 304 | = | Fallopian Tube Undifferentiated Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584210 |
| 304 | = | Female Reproductive System Carcinosarcoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584196 |
| 304 | = | Head and Neck Adenocarcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584197 |
| 304 | = | Head and Neck Cutaneous Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584198 |
| 304 | = | Head and Neck Cutaneous Squamous Cell Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584211 |
| 304 | = | High Grade B-Cell Lymphoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584219 |
| 304 | = | Hormone Receptor-Positive Breast Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584212 |
| 304 | = | Lung Squamous Cell Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584199 |
| 304 | = | Lymphoplasmacytic Lymphoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584220 |
| 304 | = | Malignant Germ Cell Tumor | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584189 |
| 304 | = | Malignant Infratentorial Neoplasm | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584221 |
| 304 | = | Malignant Renal Pelvis Neoplasm | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584213 |
| 304 | = | Malignant Small Intestinal Neoplasm | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584200 |
| 304 | = | Nasal Type Extranodal NK/T-Cell Lymphoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584214 |
| 304 | = | Oligometastatic Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584201 |
| 304 | = | Peritoneal Carcinomatosis | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584215 |
| 304 | = | Primary Peritoneal Endometrioid Adenocarcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584202 |
| 304 | = | Renal Non-Clear Cell Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584224 |
| 304 | = | Renal Pelvis Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584216 |
| 304 | = | Secondary Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584191 |
| 304 | = | Skin Basal Cell Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584203 |
| 304 | = | Small Intestinal Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584217 |
| 304 | = | Thyroid Gland Adenocarcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584204 |
| 304 | = | Type I Endometrial Adenocarcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584222 |
| 304 | = | Ureter Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584218 |
| 304 | = | Ureter Urothelial Carcinoma | 4 | 62.5 | Medium confidence | clinicaltrials | inputs
ranking row 2584223 |
| 340 | = | Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584285 |
| 340 | = | Adult Acute Lymphoblastic Leukemia | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584237 |
| 340 | = | Adult Glioblastoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584238 |
| 340 | = | Anal Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584255 |
| 340 | = | Anal Squamous Cell Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584239 |
| 340 | = | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584272 |
| 340 | = | Basaloid Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584227 |
| 340 | = | Basaloid Squamous Cell Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584240 |
| 340 | = | B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584287 |
| 340 | = | B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584256 |
| 340 | = | Breast Lobular Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584257 |
| 340 | = | Breast Tubular Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584258 |
| 340 | = | Central Nervous System Embryonal Tumor | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584225 |
| 340 | = | Childhood Lymphoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584228 |
| 340 | = | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584241 |
| 340 | = | Cutaneous Lymphoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584229 |
| 340 | = | Duodenal Adenocarcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584273 |
| 340 | = | Duodenal Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584274 |
| 340 | = | Early Stage Triple-Negative Breast Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584259 |
| 340 | = | Endometrial Clear Cell Adenocarcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584275 |
| 340 | = | Endometrial Serous Adenocarcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584260 |
| 340 | = | Essential Thrombocythemia | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584242 |
| 340 | = | Ewing Sarcoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584230 |
| 340 | = | Hepatoblastoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584226 |
| 340 | = | HER2-Positive Gastric Adenocarcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584276 |
| 340 | = | High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584281 |
| 340 | = | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584286 |
| 340 | = | High Grade Endometrial Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584277 |
| 340 | = | Leiomyosarcoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584243 |
| 340 | = | Liposarcoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584231 |
| 340 | = | Malignant Cerebellar Neoplasm | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584282 |
| 340 | = | Malignant Duodenal Neoplasm | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584261 |
| 340 | = | Malignant Gallbladder Neoplasm | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584244 |
| 340 | = | Malignant Retinal Neoplasm | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584232 |
| 340 | = | Malignant Testicular Neoplasm | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584262 |
| 340 | = | Malignant Urethral Neoplasm | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584263 |
| 340 | = | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584233 |
| 340 | = | Malignant Vaginal Neoplasm | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584264 |
| 340 | = | Medulloblastoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584234 |
| 340 | = | Megakaryocytic Neoplasm | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584235 |
| 340 | = | Osteosarcoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584236 |
| 340 | = | Periampullary Adenocarcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584283 |
| 340 | = | Platinum-Resistant Primary Peritoneal Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584245 |
| 340 | = | Primary Cutaneous Lymphoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584246 |
| 340 | = | Primary Cutaneous Non-Hodgkin Lymphoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584247 |
| 340 | = | Primary Peritoneal Clear Cell Adenocarcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584265 |
| 340 | = | Renal Pelvis Urothelial Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584278 |
| 340 | = | Retinoblastoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584248 |
| 340 | = | Small Intestinal Adenocarcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584266 |
| 340 | = | Smoldering Multiple Myeloma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584249 |
| 340 | = | Spindle Cell/Sclerosing Rhabdomyosarcoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584267 |
| 340 | = | Thyroid Gland Papillary Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584268 |
| 340 | = | Transformed B-Cell Non-Hodgkin Lymphoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584250 |
| 340 | = | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584269 |
| 340 | = | Transformed Non-Hodgkin Lymphoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584251 |
| 340 | = | Tubular Adenocarcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584252 |
| 340 | = | Type II Endometrial Adenocarcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584279 |
| 340 | = | Undifferentiated Sarcoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584253 |
| 340 | = | Urethral Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584280 |
| 340 | = | Urethral Urothelial Carcinoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584270 |
| 340 | = | Uterine Carcinosarcoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584271 |
| 340 | = | Uterine Corpus Carcinosarcoma | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584254 |
| 340 | = | Waldenstrom Macroglobulinemia | 3 | 58.1 | Medium confidence | clinicaltrials | inputs
ranking row 2584284 |
| 403 | = | Adenocarcinofibroma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584294 |
| 403 | = | Adult Hodgkin Lymphoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584319 |
| 403 | = | Adult Lymphoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584295 |
| 403 | = | Ampulla of Vater Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584392 |
| 403 | = | Anal Basaloid Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584353 |
| 403 | = | Anal Canal Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584393 |
| 403 | = | Anal Canal Cloacogenic Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584394 |
| 403 | = | Anal Canal Squamous Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584354 |
| 403 | = | Anal Non-Keratinizing Squamous Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584355 |
| 403 | = | Anaplastic Astrocytoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584296 |
| 403 | = | Astrocytoma, IDH-Mutant, Grade 3 | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584320 |
| 403 | = | Biliary Tract Adenocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584356 |
| 403 | = | B Lymphoblastic Lymphoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584321 |
| 403 | = | Botryoid-Type Embryonal Rhabdomyosarcoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584395 |
| 403 | = | Breast Mucinous Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584357 |
| 403 | = | Cervical Adenosquamous Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584396 |
| 403 | = | Cervical Squamous Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584322 |
| 403 | = | Childhood Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584297 |
| 403 | = | Childhood Central Nervous System Embryonal Tumor | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584298 |
| 403 | = | Childhood Malignant Brain Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584358 |
| 403 | = | Childhood Malignant Central Nervous System Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584323 |
| 403 | = | Childhood Malignant Digestive System Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584299 |
| 403 | = | Childhood Malignant Nervous System Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584300 |
| 403 | = | Childhood Malignant Thoracic Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584301 |
| 403 | = | Childhood Medulloblastoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584324 |
| 403 | = | Childhood Non-Hodgkin Lymphoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584325 |
| 403 | = | Choriocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584302 |
| 403 | = | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584359 |
| 403 | = | Cigarette Smoking-Related Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584303 |
| 403 | = | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584360 |
| 403 | = | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584397 |
| 403 | = | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified by Gene Expression Profile | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584413 |
| 403 | = | Double-Expressor Lymphoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584398 |
| 403 | = | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584361 |
| 403 | = | EBV-Related Lymphoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584326 |
| 403 | = | EBV-Related Malignant Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584327 |
| 403 | = | EBV-Related Non-Hodgkin Lymphoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584328 |
| 403 | = | Endometrial Dedifferentiated Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584399 |
| 403 | = | Endometrial Mixed Cell Adenocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584400 |
| 403 | = | Endometrial Undifferentiated Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584362 |
| 403 | = | Extrahepatic Cholangiocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584401 |
| 403 | = | Fallopian Tube High Grade Serous Adenocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584402 |
| 403 | = | Fallopian Tube Mucinous Adenocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584363 |
| 403 | = | Female Reproductive System Adenosquamous Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584364 |
| 403 | = | Female Reproductive System Squamous Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584329 |
| 403 | = | Follicular Helper T-Cell Lymphoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584403 |
| 403 | = | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584404 |
| 403 | = | Gallbladder Adenocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584405 |
| 403 | = | Gallbladder Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584365 |
| 403 | = | Ganglioneuroblastoma, Nodular | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584366 |
| 403 | = | Germ Cell Tumor, Brain | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584415 |
| 403 | = | Germ Cell Tumor of the Vulva | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584418 |
| 403 | = | Germinomatous Germ Cell Tumor | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584304 |
| 403 | = | Gliosarcoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584367 |
| 403 | = | Head and Neck Carcinoma of Unknown Primary | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584330 |
| 403 | = | Head and Neck Carcinoma, Other | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584417 |
| 403 | = | Head and Neck Neuroendocrine Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584305 |
| 403 | = | Head and Neck Undifferentiated Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584331 |
| 403 | = | HER2-Low Breast Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584368 |
| 403 | = | HHV8-Related Malignant Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584332 |
| 403 | = | High Grade Serous Adenocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584369 |
| 403 | = | High-Grade Serous Ovarian Cancer | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584420 |
| 403 | = | Human Papillomavirus-Related Squamous Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584333 |
| 403 | = | Interdigitating Dendritic Cell Sarcoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584306 |
| 403 | = | Invasive Bladder Urothelial Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584370 |
| 403 | = | Invasive Breast Carcinoma of No Special Type | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584371 |
| 403 | = | Invasive Urothelial Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584334 |
| 403 | = | Large Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584307 |
| 403 | = | Malignant Ampulla of Vater Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584372 |
| 403 | = | Malignant Anal Canal Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584414 |
| 403 | = | Malignant Bone Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584308 |
| 403 | = | Malignant Brain Glioma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584373 |
| 403 | = | Malignant Extragonadal Germ Cell Tumor | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584309 |
| 403 | = | Malignant Extrahepatic Bile Duct Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584374 |
| 403 | = | Malignant Histiocytic and Dendritic Cell Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584288 |
| 403 | = | Malignant Mediastinal Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584310 |
| 403 | = | Malignant Mesothelioma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584289 |
| 403 | = | Malignant Mixed Mesodermal (Mullerian) Tumor | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584311 |
| 403 | = | Malignant Ovarian Germ Cell Tumor | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584312 |
| 403 | = | Malignant Ovarian Mucinous Tumor | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584335 |
| 403 | = | Malignant Penile Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584375 |
| 403 | = | Malignant Salivary Gland Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584313 |
| 403 | = | Malignant Sinonasal Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584314 |
| 403 | = | Malignant Soft Tissue Neoplasm of Uncertain Differentiation | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584315 |
| 403 | = | Malignant Thymus Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584316 |
| 403 | = | Malignant Tongue Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584376 |
| 403 | = | Malignant Vulvar Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584377 |
| 403 | = | Mediastinal Lymphoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584336 |
| 403 | = | Merkel Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584378 |
| 403 | = | Mixed Germ Cell Tumor | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584290 |
| 403 | = | Muscle Invasive Bladder Urothelial Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584406 |
| 403 | = | Myelodysplastic Syndrome/Acute Myeloid Leukemia | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584338 |
| 403 | = | Myelodysplastic Syndrome with Excess Blasts | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584337 |
| 403 | = | Myeloid Leukemia, Philadelphia-Positive | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584339 |
| 403 | = | Neck Squamous Cell Carcinoma of Unknown Primary | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584379 |
| 403 | = | Non-Keratinizing Squamous Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584340 |
| 403 | = | Non-Seminomatous Germ Cell Tumor | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584416 |
| 403 | = | Oligometastatic Adenocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584380 |
| 403 | = | Oligometastatic Gastric Adenocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584407 |
| 403 | = | Ovarian Carcinosarcoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584381 |
| 403 | = | Ovarian Clear Cell Adenocarcinofibroma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584341 |
| 403 | = | Ovarian High Grade Serous Adenocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584408 |
| 403 | = | Ovarian Mucinous Adenocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584382 |
| 403 | = | Papillary Renal Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584383 |
| 403 | = | Pediatric-Type Diffuse Low-Grade Glioma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584419 |
| 403 | = | Platinum-Resistant Fallopian Tube Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584409 |
| 403 | = | Platinum-Sensitive Malignant Female Reproductive System Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584384 |
| 403 | = | Platinum-Sensitive Ovarian Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584385 |
| 403 | = | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584386 |
| 403 | = | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584342 |
| 403 | = | Primary Peritoneal High Grade Serous Adenocarcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584410 |
| 403 | = | Primary Peritoneal Transitional Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584343 |
| 403 | = | Primary Peritoneal Undifferentiated Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584344 |
| 403 | = | Rare Childhood Malignant Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584291 |
| 403 | = | Salivary Gland Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584345 |
| 403 | = | Sarcomatoid Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584317 |
| 403 | = | Sarcomatoid Renal Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584346 |
| 403 | = | Seminoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584347 |
| 403 | = | Sinonasal Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584348 |
| 403 | = | Sinonasal Squamous Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584387 |
| 403 | = | Soft Tissue Sarcoma of the Trunk and Extremities | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584349 |
| 403 | = | Spindle Cell Rhabdomyosarcoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584411 |
| 403 | = | Squamous Cell Carcinoma of Unknown Primary | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584388 |
| 403 | = | Superficial Basal Cell Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584389 |
| 403 | = | Synovial Sarcoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584350 |
| 403 | = | Therapy-Related Malignant Neoplasm | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584292 |
| 403 | = | Thyroid Gland Anaplastic Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584351 |
| 403 | = | Thyroid Gland Medullary Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584352 |
| 403 | = | Tobacco-Related Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584293 |
| 403 | = | Tongue Carcinoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584412 |
| 403 | = | Undifferentiated Pleomorphic Sarcoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584390 |
| 403 | = | Virus-Related Lymphoma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584318 |
| 403 | = | WHO Grade 3 Glioma | 2 | 50.3 | Medium confidence | clinicaltrials | inputs
ranking row 2584391 |
| 536 | = | Acinar Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584477 |
| 536 | = | Acral Melanoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584549 |
| 536 | = | Acute Myeloid Leukemia with FLT3/ITD Mutation | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584683 |
| 536 | = | Acute Myeloid Leukemia with FLT3 Mutation | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584665 |
| 536 | = | Acute Myeloid Leukemia with Other Genetic Abnormalities | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584614 |
| 536 | = | Adult Malignant Brain Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584615 |
| 536 | = | Adult Soft Tissue Sarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584478 |
| 536 | = | Adult T Acute Lymphoblastic Leukemia | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584550 |
| 536 | = | AIDS-Related Kaposi Sarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584479 |
| 536 | = | AIDS-Related Malignant Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584430 |
| 536 | = | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584616 |
| 536 | = | Alveolar Ridge Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584617 |
| 536 | = | Alveolar Soft Part Sarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584480 |
| 536 | = | Anal Margin Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584481 |
| 536 | = | Anal Margin Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584551 |
| 536 | = | Anaplastic Large Cell Lymphoma, ALK-Negative | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584482 |
| 536 | = | Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584666 |
| 536 | = | Ann Arbor Stage IIX (Bulky) Non-Hodgkin Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584618 |
| 536 | = | Appendix Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584483 |
| 536 | = | Astrocytoma, IDH-Mutant, Grade 4 | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584431 |
| 536 | = | B Acute Lymphoblastic Leukemia, BCR-ABL1-Like | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584619 |
| 536 | = | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584552 |
| 536 | = | BCLC Stage C Hepatocellular Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584620 |
| 536 | = | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584553 |
| 536 | = | Bone Sarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584432 |
| 536 | = | Brain Glioblastoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584484 |
| 536 | = | Breast Inflammatory Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584554 |
| 536 | = | Breast Lobular Carcinoma In Situ | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584433 |
| 536 | = | Breast Medullary Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584621 |
| 536 | = | Buccal Mucosa Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584622 |
| 536 | = | Burkitt Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584555 |
| 536 | = | Castration-Sensitive Prostate Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584623 |
| 536 | = | Central Nervous System Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584434 |
| 536 | = | Central Nervous System Leukemia | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584435 |
| 536 | = | Central Nervous System Non-Hodgkin Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584485 |
| 536 | = | Childhood Anaplastic Large Cell Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584486 |
| 536 | = | Childhood B Acute Lymphoblastic Leukemia | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584487 |
| 536 | = | Childhood B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584556 |
| 536 | = | Childhood B Lymphoblastic Leukemia/Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584436 |
| 536 | = | Childhood Colorectal Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584488 |
| 536 | = | Childhood Hepatocellular Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584489 |
| 536 | = | Childhood Hodgkin Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584490 |
| 536 | = | Childhood Lymphoblastic Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584491 |
| 536 | = | Childhood Malignant Genitourinary System Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584437 |
| 536 | = | Childhood Malignant Intestinal Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584492 |
| 536 | = | Childhood Malignant Kidney Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584493 |
| 536 | = | Childhood Malignant Liver Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584494 |
| 536 | = | Childhood Malignant Solid Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584438 |
| 536 | = | Childhood Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584557 |
| 536 | = | Childhood T Acute Lymphoblastic Leukemia | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584495 |
| 536 | = | Childhood T Lymphoblastic Leukemia/Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584439 |
| 536 | = | Choriocarcinoma Combined with Other Germ Cell Elements | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584440 |
| 536 | = | Choroid Melanoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584496 |
| 536 | = | CIC-Rearranged Sarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584558 |
| 536 | = | Classic Follicular Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584624 |
| 536 | = | Colorectal Carcinoma with Genetic Abnormalities | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584625 |
| 536 | = | Cutaneous Melanoma of the Extremity | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584497 |
| 536 | = | Cystadenocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584421 |
| 536 | = | Dedifferentiated Liposarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584499 |
| 536 | = | De Novo Myelodysplastic Syndrome | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584498 |
| 536 | = | Diffuse Intrinsic Pontine Glioma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584559 |
| 536 | = | Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584626 |
| 536 | = | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584684 |
| 536 | = | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584560 |
| 536 | = | Diffuse Midline Glioma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584561 |
| 536 | = | Diffuse Midline Glioma, H3 K27-Altered | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584627 |
| 536 | = | Diffuse Midline Glioma, H3 K27M-Mutant | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584667 |
| 536 | = | Distal Cholangiocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584668 |
| 536 | = | Early Gastric Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584669 |
| 536 | = | Early T Precursor Acute Lymphoblastic Leukemia | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584562 |
| 536 | = | Early T Precursor Lymphoblastic Leukemia/Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584500 |
| 536 | = | Embryonal Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584441 |
| 536 | = | Estrogen Receptor-Positive Breast Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584628 |
| 536 | = | Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor of Bone | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584442 |
| 536 | = | EWSR1-Negative Small Round Cell Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584501 |
| 536 | = | Extragonadal Embryonal Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584502 |
| 536 | = | Extragonadal Germinomatous Germ Cell Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584503 |
| 536 | = | Extragonadal Seminoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584563 |
| 536 | = | Extraskeletal Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584443 |
| 536 | = | Eye Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584444 |
| 536 | = | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584504 |
| 536 | = | Fibrolamellar Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584564 |
| 536 | = | Floor of Mouth Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584629 |
| 536 | = | Floor of the Mouth Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584630 |
| 536 | = | Follicular Lymphoma with Unusual Cytological Features | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584631 |
| 536 | = | Fusion-Negative Alveolar Rhabdomyosarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584632 |
| 536 | = | Fusion-Negative Rhabdomyosarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584565 |
| 536 | = | Gastrointestinal Neuroendocrine Tumors of the Esophagus/Stomach | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584688 |
| 536 | = | Germinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584566 |
| 536 | = | Gingival Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584633 |
| 536 | = | Gingival Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584634 |
| 536 | = | Grade 3b Follicular Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584635 |
| 536 | = | Grade 3 Follicular Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584567 |
| 536 | = | Hairy Cell Leukemia | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584445 |
| 536 | = | Hard Palate Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584670 |
| 536 | = | Hard Palate Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584671 |
| 536 | = | Hematologic Neoplasm Associated with Down Syndrome | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584568 |
| 536 | = | Hematologic Neoplasm with Germline Predisposition | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584446 |
| 536 | = | Hematologic Neoplasm with Germline Predisposition Associated with a Constitutional Disorder Affecting Multiple Organ Systems | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584505 |
| 536 | = | Hepatocellular Carcinoma by BCLC Stage | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584569 |
| 536 | = | Hepatocellular Malignant Neoplasm, Not Otherwise Specified | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584447 |
| 536 | = | HER2-Positive Colorectal Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584672 |
| 536 | = | Hereditary Malignant Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584422 |
| 536 | = | HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584506 |
| 536 | = | High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584686 |
| 536 | = | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584685 |
| 536 | = | High Grade Endometrioid Adenocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584507 |
| 536 | = | High-Grade Glioma, NOS | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584691 |
| 536 | = | High Grade Sarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584448 |
| 536 | = | Human Papillomavirus-Independent Penile Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584570 |
| 536 | = | Human Papillomavirus-Related Head and Neck Mucosal Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584571 |
| 536 | = | Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584673 |
| 536 | = | Human Papillomavirus-Related Pharyngeal Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584636 |
| 536 | = | Immunodeficiency-Related Malignant Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584423 |
| 536 | = | Indolent T-Cell Non-Hodgkin Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584637 |
| 536 | = | Intravascular Large B-Cell Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584638 |
| 536 | = | Invasive Breast Lobular Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584572 |
| 536 | = | Invasive Renal Pelvis and Ureter Urothelial Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584573 |
| 536 | = | Juvenile Myelomonocytic Leukemia | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584449 |
| 536 | = | Kaposi Sarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584574 |
| 536 | = | Kidney Wilms Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584450 |
| 536 | = | Laryngeal Verrucous Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584575 |
| 536 | = | Lip Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584576 |
| 536 | = | Lip Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584639 |
| 536 | = | Lower Alveolar Ridge Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584674 |
| 536 | = | Low Grade Serous Adenocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584577 |
| 536 | = | Low-Grade Serous Ovarian Cancer | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584693 |
| 536 | = | Lung Adenosquamous Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584578 |
| 536 | = | Lung Non-Small Cell Carcinoma with Genetic Abnormalities | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584579 |
| 536 | = | Lung Non-Small Cell Squamous Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584580 |
| 536 | = | Lymphocyte-Rich Classic Hodgkin Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584581 |
| 536 | = | Lymphoma by Ann Arbor Stage | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584508 |
| 536 | = | Lymphoma by Stage | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584451 |
| 536 | = | Malignant Abdominal Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584424 |
| 536 | = | Malignant Appendix Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584452 |
| 536 | = | Malignant Blood Vessel Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584509 |
| 536 | = | Malignant Brain Stem Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584675 |
| 536 | = | Malignant Buccal Mucosa Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584582 |
| 536 | = | Malignant Cardiovascular Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584425 |
| 536 | = | Malignant Central Nervous System Germ Cell Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584510 |
| 536 | = | Malignant Choroid Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584511 |
| 536 | = | Malignant Esophageal Neoplasm by Anatomic Region | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584512 |
| 536 | = | Malignant Extragonadal Nongerminomatous Germ Cell Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584453 |
| 536 | = | Malignant Floor of the Mouth Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584583 |
| 536 | = | Malignant Gingival Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584584 |
| 536 | = | Malignant Hard Palate Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584640 |
| 536 | = | Malignant Lip Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584513 |
| 536 | = | Malignant Lung and Pleural Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584454 |
| 536 | = | Malignant Major Salivary Gland Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584514 |
| 536 | = | Malignant Nasal Cavity Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584515 |
| 536 | = | Malignant Neoplasm of the Thoracic Esophagus | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584585 |
| 536 | = | Malignant Ovarian Teratoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584516 |
| 536 | = | Malignant Palate Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584586 |
| 536 | = | Malignant Pelvic Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584426 |
| 536 | = | Malignant Retroperitoneal Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584455 |
| 536 | = | Malignant Splenic Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584427 |
| 536 | = | Malignant Teratoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584456 |
| 536 | = | Malignant Testicular Germ Cell Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584457 |
| 536 | = | Malignant Vascular Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584458 |
| 536 | = | Mediastinal Non-Hodgkin Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584517 |
| 536 | = | Melanoma of Unknown Primary | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584518 |
| 536 | = | MGMT-Methylated Glioblastoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584587 |
| 536 | = | MGMT-Unmethylated Glioblastoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584588 |
| 536 | = | Microsatellite Stable Colon Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584676 |
| 536 | = | Microsatellite Stable Colorectal Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584641 |
| 536 | = | Mixed Cell Type Kidney Wilms Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584519 |
| 536 | = | Mucinous Cystadenocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584459 |
| 536 | = | Mucosal Melanoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584520 |
| 536 | = | Muscle Invasive Renal Pelvis and Ureter Urothelial Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584642 |
| 536 | = | Muscle Invasive Renal Pelvis Urothelial Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584677 |
| 536 | = | Muscle Invasive Ureter Urothelial Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584678 |
| 536 | = | Muscle Invasive Urethral Urothelial Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584589 |
| 536 | = | Mycosis Fungoides | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584590 |
| 536 | = | Mycosis Fungoides and Sezary Syndrome | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584643 |
| 536 | = | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584521 |
| 536 | = | Myeloid Leukemia Associated with Down Syndrome | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584460 |
| 536 | = | Myeloid Neoplasm Post Cytotoxic Therapy | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584461 |
| 536 | = | Nasal Cavity Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584591 |
| 536 | = | Nasal Cavity Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584644 |
| 536 | = | Nasopharyngeal Carcinoma by AJCC v8 Stage | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584679 |
| 536 | = | Nasopharyngeal Carcinoma by AJCC v9 Stage | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584680 |
| 536 | = | Nasopharyngeal Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584645 |
| 536 | = | Nodal Peripheral T-Cell Lymphoma with TFH Phenotype | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584695 |
| 536 | = | Nodular Lymphocyte Predominant B-Cell Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584462 |
| 536 | = | Non-Hodgkin Lymphoma by Ann Arbor Stage | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584522 |
| 536 | = | Obesity-Related Malignant Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584428 |
| 536 | = | Oligometastatic Breast Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584592 |
| 536 | = | Oligometastatic Esophageal Adenocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584646 |
| 536 | = | Oligometastatic Malignant Solid Neoplasm | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584523 |
| 536 | = | Oligometastatic Prostate Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584593 |
| 536 | = | Oral Cavity Verrucous Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584594 |
| 536 | = | Oropharynx Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584692 |
| 536 | = | Ovarian Cancer, Other | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584687 |
| 536 | = | Ovarian Choriocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584524 |
| 536 | = | Ovarian Cystadenocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584463 |
| 536 | = | Ovarian High Grade Endometrioid Adenocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584595 |
| 536 | = | Ovarian Low Grade Serous Adenocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584647 |
| 536 | = | Ovarian Mucinous Cystadenocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584525 |
| 536 | = | Palate Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584648 |
| 536 | = | Palate Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584649 |
| 536 | = | Pancreatic Acinar Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584596 |
| 536 | = | Pancreatic Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584526 |
| 536 | = | Papillary Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584527 |
| 536 | = | Parathyroid Cancer | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584689 |
| 536 | = | Pediatric-Type Diffuse High-Grade Glioma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584690 |
| 536 | = | Penile Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584597 |
| 536 | = | Penile Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584528 |
| 536 | = | Penile Squamous Cell Carcinoma, Usual Type | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584650 |
| 536 | = | Peripheral Primitive Neuroectodermal Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584464 |
| 536 | = | Peripheral Primitive Neuroectodermal Tumor of Bone | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584529 |
| 536 | = | Peripheral Primitive Neuroectodermal Tumor of Soft Tissues | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584530 |
| 536 | = | Pharyngeal Carcinoma by AJCC v8 Stage | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584651 |
| 536 | = | Pharyngeal Carcinoma by AJCC v9 Stage | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584652 |
| 536 | = | Plasmablastic Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584653 |
| 536 | = | Plasma Cell Leukemia | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584465 |
| 536 | = | Plasmacytoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584466 |
| 536 | = | Pleuropulmonary Blastoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584467 |
| 536 | = | Prefibrotic Primary Myelofibrosis | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584654 |
| 536 | = | Primary Central Nervous System Non-Hodgkin Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584598 |
| 536 | = | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584599 |
| 536 | = | Primary Cutaneous Diffuse Large B-Cell Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584655 |
| 536 | = | Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584600 |
| 536 | = | Primary Intraocular Non-Hodgkin Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584531 |
| 536 | = | Primary Mediastinal Large B-Cell Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584601 |
| 536 | = | Primary Peritoneal Carcinosarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584532 |
| 536 | = | Primary Peritoneal Low Grade Serous Adenocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584656 |
| 536 | = | Primary Vitreoretinal Non-Hodgkin Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584602 |
| 536 | = | Pseudomyxoma Peritonei | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584603 |
| 536 | = | Retromolar Trigone Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584681 |
| 536 | = | Retroperitoneal Sarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584533 |
| 536 | = | Rhabdoid Tumor of the Kidney | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584468 |
| 536 | = | Round Cell Sarcoma with EWSR1-non-ETS Fusion | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584534 |
| 536 | = | Salivary Gland Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584604 |
| 536 | = | Sarcoma with BCOR Genetic Alterations | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584535 |
| 536 | = | Sclerosing Rhabdomyosarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584657 |
| 536 | = | Secondary Myelodysplastic Syndrome | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584469 |
| 536 | = | Skin Nodular Basal Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584605 |
| 536 | = | Skin Sclerosing/Morphoeic Basal Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584606 |
| 536 | = | Small Cell Sarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584470 |
| 536 | = | Solid Alveolar Rhabdomyosarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584658 |
| 536 | = | Solid Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584471 |
| 536 | = | Splenic Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584472 |
| 536 | = | Splenic Marginal Zone Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584607 |
| 536 | = | Splenic Non-Hodgkin Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584536 |
| 536 | = | Sporadic Gastric Adenocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584659 |
| 536 | = | Squamous Cell Carcinoma In Situ | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584537 |
| 536 | = | Systemic Anaplastic Large Cell Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584538 |
| 536 | = | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584660 |
| 536 | = | Testicular Leukemia | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584473 |
| 536 | = | Testicular Mixed Choriocarcinoma and Embryonal Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584540 |
| 536 | = | Testicular Mixed Choriocarcinoma and Teratoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584541 |
| 536 | = | Testicular Mixed Choriocarcinoma and Yolk Sac Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584542 |
| 536 | = | Testicular Mixed Germ Cell Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584474 |
| 536 | = | Thoracic Esophagus Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584608 |
| 536 | = | Thymus Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584475 |
| 536 | = | Thymus Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584543 |
| 536 | = | T Lymphoblastic Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584539 |
| 536 | = | Tongue Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584661 |
| 536 | = | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584609 |
| 536 | = | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584610 |
| 536 | = | Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584662 |
| 536 | = | Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584663 |
| 536 | = | Unclassified Renal Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584694 |
| 536 | = | Undifferentiated Round Cell Sarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584611 |
| 536 | = | Upper Alveolar Ridge Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584682 |
| 536 | = | Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584612 |
| 536 | = | Uterine Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584544 |
| 536 | = | Vaginal Adenocarcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584545 |
| 536 | = | Vaginal Adenosquamous Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584664 |
| 536 | = | Vaginal Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584613 |
| 536 | = | Vaginal Squamous Cell Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584546 |
| 536 | = | Verrucous Carcinoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584547 |
| 536 | = | Virus-Related Sarcoma | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584548 |
| 536 | = | Wilms Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584429 |
| 536 | = | Yolk Sac Tumor | 1 | 33.9 | Medium confidence | clinicaltrials | inputs
ranking row 2584476 |
Data updated 16 hours agoSource updated unknown810 eligible entities · inputs hash 56fba75197c8c0044b9e345f